105.70
+1.07(+1.02%)
Currency In USD
| Previous Close | 104.63 |
| Open | 104.63 |
| Day High | 107.5 |
| Day Low | 103.55 |
| 52-Week High | 116 |
| 52-Week Low | 45.91 |
| Volume | 542,096 |
| Average Volume | 659,884 |
| Market Cap | 7.05B |
| PE | -34.1 |
| EPS | -3.1 |
| Moving Average 50 Days | 103.98 |
| Moving Average 200 Days | 79.9 |
| Change | 1.07 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $4,301.99 as of December 04, 2025 at a share price of $105.7. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $3,649.86 as of December 04, 2025 at a share price of $105.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically mean
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
GlobeNewswire Inc.
Nov 07, 2025 12:30 PM GMT
-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
GlobeNewswire Inc.
Nov 05, 2025 9:01 PM GMT
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHBBOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RY